Erica Lorenzon

Supplementary Figure 3 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 201K, A2V CrossMab characterization and safety profile

Supplementary Figure 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 169K, Schematic representation of Ang2-VEGF-A CrossMab (RO5520985) and binding properties

Supplementary Figure 6 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 135K, Analysis of hypoxia during Ang-2-VEGF-A inhibition

Supplementary Figure 4 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 67K, A2V CrossMab treatment inhibits angiogenesis in the VEGF-induced cornea pocket assay

Supplementary Figure 2 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 188K, Cross-reactivity and binding affinities of A2V CrossMab and the comparator molecules bevacizumab and LC06

Supplementary Figure 5 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 138K, Ex vivo mode of action analysis of Ang-2-VEGF-A inhibition

Supplementary Figure 7 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 69K, Ang-2 induced VEGFR-2 upregulation

Supplementary Table 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 52K, An overview of the antibodies used in the present study

Supplementary Figure 6 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 135K, Analysis of hypoxia during Ang-2-VEGF-A inhibition

Supplementary Figure 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 169K, Schematic representation of Ang2-VEGF-A CrossMab (RO5520985) and binding properties

Supplementary Figure 7 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 69K, Ang-2 induced VEGFR-2 upregulation

Supplementary Material from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Georg Klein, Werner Scheuer, Romi Raemsch et autres

PDF file 108K, Detailed description of experimental procedures

ch, de, sg, gb (code pays fourni par la source)